Merck presents positive results from phase 1/2 study evaluating V116
V116 designed to target serotypes that account for 85% of all invasive pneumococcal disease in individuals aged 65 and over in the United States as of 2019
V116 designed to target serotypes that account for 85% of all invasive pneumococcal disease in individuals aged 65 and over in the United States as of 2019
Bioresource Technology's state of the art manufacturing facility in Weston, Florida
Gilman will be responsible for all business development and portfolio strategy efforts globally.
The three-year collaboration will focus on the development of new tools for computational chemistry modelling as well as new molecular representations to advance the next generation of molecular machine learning
Becomes the first airline globally to develop and launch sustainable, temperature-controlled containers for the transportation of pharmaceuticals
Acceptance based on results from the phase 3 KEYNOTE-091 trial
Strides was granted a Competitive Generic Therapy (CGT) designation for its ANDA.
During the research term, Olema will contribute funding to Aurigene to facilitate ongoing discovery efforts.
Steinberg brings nearly three decades of experience in biopharmaceutical equity research to Prolacta's executive team.
Co-marketing agreement between Thermo Fisher Scientific and TransMIT allows for high spatial and high mass resolution MSI platform to study complex biological tissues
Subscribe To Our Newsletter & Stay Updated